Table 5. Clinical response according to LMR-week 6 for hepatic carcinoma patients.
Response | Number (N=36, %) | Low LMR-week 6 (N=21, 58.3%) | High LMR-week 6 (N=15, 41.7%) |
---|---|---|---|
CR | 1 (2.8) | 0 (0.0) | 1 (6.7) |
PR | 6 (16.7) | 2 (9.5) | 4 (26.7) |
SD | 9 (25.0) | 6 (28.6) | 3 (20.0) |
PD | 20 (55.5) | 13 (61.9) | 7 (46.6) |
N, number; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; LMR-week 6, lymphocyte-to-monocyte ratio 6 weeks after the start of PD-1 inhibitors.